Highlights of prescribing information the recommended dose of. Adjust the dose based on the patients inr and the condition being treated. Sulfuric acid andor dibasic sodium phosphate heptahydrate may have been added for ph adjustment. Per the prescribing information, idarucizumab should be cleared within 24 hours of administration, and coagulation parameters should return to normal. Csl behring immune globulin intravenous human, 10% liquid privigen us package insert july 2007 page 4 version 10. View important safety information and full prescribing information on website. Learn how pradaxa can help reduce the risk of stroke in afib not caused by a heart valve problem. Infuvite adult multiple vitamins for infusion pharmacy bulk package infuvite pediatric multiple vitamins for infusion infuvite pediatric multiple vitamins for infusion pharmacy bulk package ndc 5464356491 5464356492 5464356461 5464356470 not more than 30 mcgl for infuvite pediatric. Effective hemostasis measured up to 24 hours for the acute major bleeding trial and until the end of procedure up to 24 hours for the urgent surgeryinvasive procedures trial.
Coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Download instruction for use pdf praxbind is for intravenous use only. Annexa4 interim data set, prior to day 30 from the prescribing information. Jan 01, 2020 use aseptic technique when administering praxbind. Other referenced trademarks are owned by third parties. Actemra tocilizumab injection, for intravenous or subcutaneous use initial u. Please see important safety information and full prescribing information, including boxed warning.
Prophylaxis of dvt following hip or knee replacement. Praxbind is a specific reversal agent for dabigatran and is indicated in. Cytokine release syndrome and neurological toxicities see full prescribing information for complete boxed warning. In 2 headtohead trials, kcentra demonstrated superiority to plasma in 3 of 4 efficacy endpoints. Burlington, on may 16, 2016 boehringer ingelheim canada ltd. Pradaxa dabigatran as well as other newer oral anticoagulants have surged in popularity over warfarin due to not having to get frequent blood draws and no. See the end of section 4 for how to report side effects. Andexxa coagulation factor xa recombinant, inactivated. One daily 10 ml dose should be added directly to not less than 500 ml, and preferably ml, of intravenous dextrose, saline or similar infusion solutions. There are limited data to support administration of an additional 5 g. Praxbind fda prescribing information, side effects and uses. Serious infections leading to hospitalization or death including. Cytokine release syndrome crs, which may be lifethreatening or fatal, occurred in patients receiving blincyto.
Actemra subcutaneous formulation is not intended for intravenous. Fda provides full approval to praxbind, specific reversal. Pradaxa dabigatran etexilate mesylate capsules is indicated. Find easy to use information on the recommended dose and download preparation instructions for praxbind. Product information for auspar praxbind boehringer ingelheim pty ltd pm.
Choose pradaxa dabigatran etexilate for afib, dvt or pe. Praxbind idarucizumab injection, for intravenous use initial u. Prophylaxis of dvt following hip or knee replacement surgery. Pradaxa dabigatran etexilate mesylate capsules, for oral use. Jan 01, 2020 praxbind idarucizumab is supplied in 2 singledose vials, each containing 2. Ensure aseptic handling when preparing the infusion. Idarucizumab is indicated for patients treated with dabigatran when reversal of. Fda approves praxbind idarucizumab, specific reversal. Table 1 presents adverse events reported in healthy volunteers treated with placebo alone, praxbind alone and those treated either praxbind alone or treated with praxbind after pretreatment with dabigatran etexilate. In the studies, the reversal effects of praxbind were evident immediately, within minutes after administration of 5 grams of praxbind. Fda provides full approval to praxbind, specific reversal agent for pradaxa decision converts praxbind s idarucizumab accelerated approval, granted in october 2015, to full approval. This will allow quick identification of new safety information. Bolus injection by injecting both vials consecutively one after another via syringe see figure 3.
Actemra subcutaneous formulation is not intended for. Praxbind product monograph schedule d page 7 of 30 rates. The enclosed package leaflet contains additional information for healthcare professionals. Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals oa. Fragmin dalteparin sodium injection for subcutaneous. See how pradaxa compares to warfarin, and find dosing and coverage information. Praxbind, innidarucizumab european medicines agency europa. Praxbind idarucizumab is a sterile, preservativefree, colorless to slightly yellow, clear to slightly opalescent solution for intravenous administration.
Lift the package away from the adapter and discard the package. Dabigatran treatment can be initiated 24 hr after administration of idarucizumab. Place the diluents vial on a flat and solid surface. Praxbind is a reversal agent specific for dabigatran pradaxa, a blood thinner medicine that blocks a substance in the body, which is involved in blood clot. Andexxa coagulation factor xa recombinant, inactivatedzhzo is a recombinant modified human factor xa fxa protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to lifethreatening or uncontrolled bleeding. Triplett, chad anticoagulants for venous thromboembolism. Adjust the timing of the dose on postoperative day 1 accordingly. Connect the diluent syringe to the vial adapter by inserting the tip of the syringe into the adapter opening while firmly pushing and turning the syringe clockwise until the connection is secured. Do not administer infuvite adult pharmacy bulk package as a direct, undiluted intravenous injection as it may give rise to dizziness, faintness, and possible tissue irritation. Ridgefield, ct, october, 16, 2015 boehringer ingelheim pharmaceuticals, inc. Highlights of prescribing information these highlights do not. Kcentra, prothrombin complex concentrate human, is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin k antagonist vkaeg, warfarin therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure.
Bulk package for intravenous feeding should be done by transferring the contents of vial 1 into the contents of vial 2 to provide ten 10 ml single doses. Access praxbind prescribing information, dosage, preparation, and administration information. Immune globulin intravenous human, 10% liquid privigen. Prescribing information kcentra prothrombin complex. Idarucizumab is a humanized monoclonal antibody fragment fab derived from an igg1 isotype molecule, whose target is the direct thrombin inhibitor dabigatran. If side effects occur, the infusion should be slowed or stopped until the symptoms subside.
Fda provides full approval to praxbind, specific reversal agent for pradaxa decision converts praxbinds idarucizumab accelerated approval, granted in october 2015, to full approval. Praxbind idarucizumab injection, for intravenous use. Idarucizumab praxbind national drug monograph december 2015. A preexisting intravenous line may be used for administration of praxbind. Also learn about solutionsplus, and inside rx programs. Page 2 of 21 full prescribing information 1 indications and usage 1. Package insert protamine sulfate injection, usppiengv1. Praxbind idarucizumab is supplied in 2 singledose vials, each containing 2. Fdaapproved reversal treatment available in all 50 states. A premature discontinuation of pradaxa increases the risk of thrombotic events, and b spinalepidural hematoma see full prescribing information for complete boxed warning procedures when possible, then restart promptly 2. This medicinal product is subject to additional monitoring. Highlights of prescribing information these highlights. Dec 31, 2019 protamine sulfate injection, usp is a sterile, isotonic solution of protamine sulfate.
Dailymed protamine sulfate protamine sulfate injection. Infuvite adult pharmacy bulk package is ready for immediate use in adults and children aged 11 years and older when added to intravenous infusion fluids. Praxbind idarucizumab dosing, indications, interactions. Praxbindone recommended dose for all pradaxa patients. Protamine sulfate injection, usp is a sterile, isotonic solution of protamine sulfate. Jan 01, 2020 the recommended dose of praxbind is 5 g, provided as two separate vials each containing 2. Turn the package over and insert the clear plastic spike through the diluent stopper by pressing straight down fig. The dosage and administration of coumadin must be individualized for each patient according to the patients international normalized ratio inr response to the drug. There is limited data to support administration of an additional 5 g of praxbind see warnings and precautions. Blincyto blinatumomab for injection, for intravenous use initial u. You can help by reporting any side effects you may get. Pradaxa is the only noac with a specific reversal, available in all 50 states. Pradaxa dabigatran as well as other newer oral anticoagulants have surged in popularity over warfarin due to not having to get frequent blood draws and no restrictions to regulate how much green leafy vegetables you consume.
The application included data from healthy volunteers as well as results from an interim analysis of the reverse ad trial nct02104947. Each 50 ml vial of praxbind solution for injectioninfusion contains 2. This indication is approved under accelerated approval based on the. Nucala mepolizumab for injection nucala mepolizumab. Reversing dabigatran exposes patients to the thrombotic risk of their underlying disease so resume anticoagulant as soon as medically appropriate reelevation of coagulation parameters. Risk of serious infections see full prescribing information for complete boxed warning. Praxbind was approved under an accelerated approval pathway. Product approval information is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to lifethreatening or uncontrolled bleeding. Reversal of dabigatran bleeding and coagulopathy using ncbi. Praxbind is indicated in patients treated with pradaxa when reversal of the anticoagulant effects of dabigatran is needed. View important safety information and full prescribing information on. Parenteral drug products should be inspected visually for. In a subset of patients, recurrence of plasma concentrations of unbound dabigatran and concomitant prolongation of clotting tests have occurred up to 24 hours after administration of idarucizumab see section 5.
1470 1502 121 412 68 283 439 291 558 1289 1467 824 872 1208 373 793 982 1344 481 886 385 1213 1358 1321 1130 1310 509 1209 1313 1145 1045 1050 277 413 1399 879 1098 898 1271 428 661 799 1116 56 947